Medicare Pilot Allows THC‑CBD Mix
A Medicare/Medicaid pilot is permitting 3mg THC in CBD products for coverage—an unusual move that may clash with current hemp laws and create planning questions for older beneficiaries using CBD. The change could affect discussions around product safety and benefit coverage. (x.com)
CMS posted updated program details saying eligible beneficiaries may receive hemp-derived products through participating organizations starting April 1, 2026. (themarijuanaherald.com) The agency limited participation to orally administered formulations and explicitly excluded inhalable products and cannabinoids not naturally produced by the marijuana plant. (themarijuanaherald.com) The pilot was described in a Federal Register notice tied to proposed Medicare Advantage and Part D policy changes for contract year 2027, with the rulemaking docket opening for public comment through January 26, 2026. (federalregister.gov) Charlotte’s Web announced it will act as a premier CBD provider for the pilot, offering product access through an online healthcare portal aimed at older oncology patients beginning in early 2026. (investors.charlottesweb.com) State hemp regulations already set divergent potency limits — Virginia caps total THC at two milligrams per package, Florida’s law sets a five‑milligram per‑serving ceiling in recent legislation, and Maryland defines intoxicating products at thresholds as low as 0.5 mg per serving or 2.5 mg per package. (vdacs.virginia.gov) CMS’s proposal frames the pilot as evidence‑gathering focused on product quality, dosing consistency and patient outcomes and signals a preference for FDA‑regulated or pharmaceutically manufactured formulations. (federalregister.gov) Industry participants and issuers have given mixed signals on timing: some companies working with CMS cite an early‑2026 rollout target, while trade reporting noted CMS had not publicly set an official launch date as of March 19, 2026. (ir.cvsciences.com)
